BiomX Inc

BiomX Inc is an Israeli biotechnology startup founded in 2015, specializing in customized phage therapies to eradicate harmful bacteria in chronic diseases. The company's slogan is "Customized phage therapies to eradicate harmful bacteria in chronic diseases." BiomX is at the forefront of developing both natural and engineered phage cocktails to specifically target and destroy bacteria impacting skin appearance and those present in chronic diseases such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis, and colorectal cancer. Through its innovative approach, BiomX discovers and validates proprietary bacterial targets, customizing phage compositions to combat these specific targets. In the latest funding round, BiomX raised a substantial $50.00M in Post-IPO Equity investment on 06 March 2024. The investors in this round included prominent names such as OrbiMed, Cystic Fibrosis Foundation, Deerfield Management, Nantahala Capital, and the AMR Action Fund. With a focus on the biotechnology and healthcare industries, BiomX is poised to make a significant impact in the treatment of chronic diseases through its pioneering phage therapies.